Lawrence Goldstick - Concepedia

Author

Lawrence Goldstick

Also Known As

Justin Delange, L. Goldstick, L. P. Goldstick, Lawrence Goldstick, Lawrence P Goldstick, Lawrence P. Goldstick, Mark Goldstein

Publications

3.7K

Citations

H-Index

Concepts

All Affiliations

Cleveland Clinic McGill University NeuroRx Research (Canada)Inserm Queen Mary University of London

About

Lawrence Goldstick is an author at Cleveland Clinic specializing in neurology, medicine, and clinical trials.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	1.2K
2	Neurology	5	5	1.2K
3	Health Sciences	1	1	896
4	Social Sciences	1	1	31
5	Neuroscience	1	1	31

Lawrence Goldstick

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study Ludwig Kappos, Amit Bar‐Or, Bruce Cree, The Lancet Neurological DisorderClinical NeurologyClinical TrialsSiponimod Versus PlaceboNeurological Monitoring	2018	896
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial Daniel S. Reich, Douglas L. Arnold, Patrick Vermersch, The Lancet Neurology Neurological DisorderPhase 2BClinical TrialsPlacebo-controlled TrialPharmacotherapy	2021	177
Ictus emeticus Ronald E. Kramer, Hans O. Lüders, Lawrence Goldstick, Neurology	1988	108
Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS Robert J. Fox, Andrew Chan, Ralf Gold, Neurology Clinical Practice	2016	104
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial John Foley, Gilles Defer, Lana Zhovtis Ryerson, The Lancet Neurology Relapsing-remitting Multiple SclerosisClinical NeurologyClinical TrialsNeurological ProgressTreatment Option	2022	103
Ipsilateral forced head and eye turning at the end of the generalized tonic‐clonic phase of versive seizures Elaine Wyllie, Hans O. Lüders, Harold H. Morris, Neurology NeuropsychologyNeurological DisorderBrain LesionOptic NerveElectroencephalography	1986	31
First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis Bruce Hughes, Mark Cascione, Mark S. Freedman, Multiple Sclerosis and Related Disorders Disease ProgressionFirst-dose EffectsClinical TrialsTreatment OptionOutcomes Research	2014	13

Page 1